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Abstract
Background: There are currently no standard diagnostic criteria for characterizing advanced Parkinson’s disease
(APD) in clinical practice, a critical component in determining ongoing clinical care and therapeutic strategies,
including transitioning to device-aided treatment. The goal of this analysis was to determine the proportion of APD
vs. non-advanced PD (non-APD) patients attending specialist PD clinics and to demonstrate the clinical burden of
APD.
Methods: OBSERVE-PD, a cross-sectional, international, observational study, was conducted with 2615 PD patients
at 128 movement disorder centers in 18 countries. Motor and non-motor symptoms, activities of daily living, and
quality-of-life end points were assessed. The correlation between physician’s global assessment of advanced PD and
the advanced PD criteria from a consensus of an international group of experts (Delphi criteria for APD) were
evaluated.
Results: According to physician’s judgment, 51% of patients were considered to have APD. There was a moderate
correlation between physician’s judgment and Delphi criteria for APD (K = 0.430; 95% CI 0.406–0.473). Activities of
daily living, motor symptom severity, dyskinesia duration/disability, “Off” time duration, non-motor symptoms, and
quality-of-life scores were worse among APD vs. non-APD patients (p < 0.0001 for all). APD patients (assessed by
physicians) had higher disease burden by motor and non-motor symptoms compared with non-APD patients and a
negative impact on activities of daily living and quality of life.
Conclusions: These findings aid in identifying standard APD classification parameters for use in practicing
physicians. Improvements in identification of APD patients may be particularly relevant for optimizing treatment
strategies including transitioning to device-aided treatment.
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Background
Patient progression to advanced Parkinson’s disease
(APD) has conventionally not been well-defined. The
worsening of cardinal features of PD (e.g. tremor,
rigidity, akinesia, and postural instability) are inevitable
as disease progression occurs. The onset of motor fluc-
tuations and/or levodopa-induced dyskinesia is com-
monly accepted as a marker of progression of the
disease; however, determining the point at which a pa-
tient is classified as having APD is not distinct and
imposes continued challenges, particularly when deter-
mining appropriate therapeutic recommendations for
optimization of patient outcomes. Although commonly
used in routine clinical practice to identify the clinical
stages of PD, the Hoehn and Yahr scale has limitations
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[1], including limited capture of motor and non-motor
symptoms (NMS) and inability to measure quality of life
(QoL) [2–4].
As PD symptoms become increasingly refractory to
oral treatments, device-aided treatment (DAT) (i.e. treat-
ment that extends beyond oral medications) such as
stereotactic surgery for deep brain stimulation (DBS)
and infusion therapies—namely continuous subcutane-
ous apomorphine infusion (CSAI) or levodopa-carbidopa
intestinal gel (LCIG)—may be considered [5, 6]. Switch-
ing from oral PD treatment to invasive therapeutics is
typically determined in movement disorder centers/
clinics that provide comprehensive treatment by a multi-
disciplinary expert group. Even within these clinics there
are variable reports on percentages of APD patients [7–9],
highlighting potential discrepancies between identifica-
tion, categorization, and total number of APD patients.
Differences in practice patterns between general neurolo-
gists and movement disorder specialists may contribute to
these discrepancies. Consistent identification and
categorization of APD patients in movement disorder
clinics is critical for these centers to provide sufficient re-
sources for patient education for APD symptom manage-
ment and key information on DAT. Standardized criteria
may also have an educational effect for the non-
specialized neurologist who can then monitor patients for
specific symptoms and refer patients in real time when
treatment optimization is still possible.
The OBSERVE-PD (OBSERVational, cross-sEctional
PD) study was designed to determine the proportion of
patients with APD in movement disorder clinics in dif-
ferent regions. Predefined objectives included the
characterization of clinical and non-clinical features
based on physician’s judgment and newly developed Del-
phi criteria for APD, as well as a comparison of the two
assessments’ determination of APD [10]. Additionally,
characteristics of APD patients were examined based on
DAT-eligibility.
Methods
Study setting and patient selection
Movement disorder clinics were selected based on DAT
availability (i.e. LCIG, CSAI, or DBS) offered by an ex-
pert/specialist team. This observation study included PD
patients who were attending a routine clinical visit or
were inpatients at participating movement disorder
clinics. Consecutive patients were asked for their interest
in participation and were enrolled in the study at each
site to avoid selection bias. To be included in the study,
patients had to be at least 18 years old with a clinical
diagnosis of PD. Patients had to sign an authorization
form to disclose personal health information and an in-
formed consent form and be fluent in the language of
the provided patient questionnaire. Patients were
excluded if in the “Off” stage at the time of visit, if there
was significant uncertainty around the PD diagnosis (i.e.
symptoms suggesting non-idiopathic PD such as early
falls or early autonomic disturbances, lack of levodopa
responsiveness, supranuclear gaze disturbances, history
of repeated strokes with stepwise progression of parkin-
sonism), or if patients were participating in a concurrent
clinical study. The study was approved by local ethics
committees and performed according to the Inter-
national Conference on Harmonization and Good
Clinical Practice requirements, in accord with the princi-
ples of the Declaration of Helsinki.
Study assessments
Following signed consent, data were collected from each
patient at a single study visit. Patient records provided
demographic information (age, sex, race, patient resi-
dence, and caregiver support), cognitive function
(assessed in the case report form in a general manner,
not using a scale), PD-related information (date of diag-
nosis, referral history, and disease stage based on physi-
cian’s judgment), PD treatment information (PD
treatment history, patient qualification/eligibility for in-
vasive therapy according to physician’s judgment,
current PD treatment [s] and physician’s assessment of
response to current treatment), and comorbidities. Pa-
tient qualification/eligibility for DAT was not mandated
by certain eligibility criteria set forth by the study and
was instead dictated by the movement disorder special-
ist’s judgment for potential patient candidacy for DAT.
Motor symptoms assessed during the study visit in-
cluded Unified Parkinson’s Disease Rating Scale
(UPDRS) in “On” stage (includes Part II [activities of
daily living, ADL], Part III [motor complications], and
Part IV [items 32, 33, 34, and 39; complications of
therapy]), and UPDRS Part V (modified Hoehn and Yahr
scale staging). Non-motor symptoms were assessed
using the Non-motor Symptom Scale (NMSS), and QoL
was assessed using the 8-item Parkinson’s Disease
Quality of Life Questionnaire (PDQ-8).
Delphi criteria for APD
Delphi criteria for APD were developed as a staging tool
to help clinicians identify patients with APD using con-
sistent characterization, which therefore will assist in op-
timizing patient treatment care (e.g. DAT eligibility)
[10]. The Delphi versus physician judgment comparison
was a pre-defined end point. Patients were first assessed
by the investigator using their own physician’s judgment
and then assessed using the Delphi criteria. Independent
assessments were not possible as the outcomes were de-
termined by the same investigator. In this study, patients
were assessed by movement disorder specialists using 11
indicators (Table 1) of suspected APD identified through
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a Delphi consensus methodology by an international
movement disorder specialist’s expert group. Patients
having any of the indicators were identified as having
APD [10]. As APD was determined by individual
physician judgment, no comparison to other scales
was conducted. Patients with ongoing DAT were not
assessed using the Delphi criteria as the comparison
was considered invalid as they would usually
experience better clinical outcomes.
Safety
This observational study was not designed to identify or
quantify safety aspects of any therapy. Any product-related
events were reported in accord with local laws and regula-
tions to the relevant regulatory authority and/or drug mar-
keting authorization holder. Patient data were documented
on data report forms. Representatives at each center were
asked to complete a site information form.
Statistical analysis
Statistical analyses were performed using the SAS®
package, version 9.2 (SAS Institute, Cary, NC). Data
were summarized using descriptive statistics. The pri-
mary end point was the proportion of PD patients who
had APD according to physician judgment. A secondary
end point compared physicians’ judgment with the Del-
phi criteria for APD. A multivariable logistic regression
analysis was applied with physicians’ assessments of
APD as target variable and 32 potential prognostic fac-
tors including all Delphi criteria for APD, UPDRS II to
V, UPDRS IV item 32, UPDRS IV item 33, UPDRS IV
item 34, UPDRS item 39, NMSS score, PDQ-8, time
since diagnosis, current invasive PD treatment, gender,
race, education, motor fluctuations, caregiver support,
comorbidities, geographic region, occupation, and type
of residence. The correlation between the Delphi criteria
for APD and physicians’ assessments of APD were con-
firmed with an additional sensitivity analysis by exclud-
ing ongoing DAT patients to eliminate any potential
masking effect of the invasive treatment. Two-sided 95%
CIs were provided for comparative end points; CIs
and p values (two-sample t test) were calculated for
differences between APD and non-advanced PD
(non-APD) patients.
A post hoc analysis assessed baseline demographics
and disease characteristics of APD patients who were
assessed as eligible or ineligible for DAT by the treating
physician. Patient characteristics were analyzed using de-
scriptive statistics. An analysis of variance compared dis-
ease characteristics of patients eligible for DAT (ongoing
DAT versus planned DAT versus no DAT) and patients
ineligible for DAT with t tests for pairwise comparisons
between each group for selected scale scores.
Results
Comparisons between APD and non-APD patients
This study evaluated 2615 PD patients from 128 move-
ment disorder clinics in 18 countries. According to phy-
sician’s assessments, 51.3% (n = 1342) of recruited PD
patients had APD; this proportion varied regionally
(range: 24 to 82%; Table 2). There were no differences
between APD and non-APD patient percentages regarding
age, sex, and living situation (Table 3). Notable differences
were observed in caregiver support status, which was
needed by most APD patients (69.1%), whereas only
25.8% of non-APD patients had caregiver support. Most
patients (APD and non-APD) were on oral levodopa/car-
bidopa or oral dopamine agonists at the time of the study
(Additional file 1: Table S1).
Patients with physician-assessed APD had a greater
disease burden than non-APD (Fig. 1). Mean scores
for ADL, motor symptom severity, dyskinesia duration
and disability, average duration of “Off” time, NMS,
and QoL were all significantly worse among APD pa-
tients than non-APD patients (p < 0.0001 for all).
Most (87%) APD patients experienced motor fluctua-
tions (94% of DAT-eligible patients and 74% of
DAT-ineligible patients).
Delphi criteria for APD
There was a moderate correlation between physician’s
judgment of APD and classification based on all indica-
tors of APD identified by the Delphi criteria (K = 0.441;
95% CI, 0.408–0.473); there was also a moderate
correlation between individual items from the Delphi
criteria for APD and physician’s judgment (Table 4). A
sensitivity analysis, which excluded patients with on-
going DAT, confirmed the moderate correlation
Table 1 Delphi criteria for APD [10]
Delphi consensus criteria questions Patient has
1. Troublesome motor fluctuations,
severity level
Moderate or severe
2. “Off” time, hours/waking day ≥ 2 or < 2
3. Nighttime sleep disturbances,
severity level
Moderate or severe
4. Troublesome dyskinesia, hours/
waking day
2–3 or > 3
5. Non-motor fluctuations present Yes
6. “Off” time at least every 3 h Yes
7. ≥ 5 times daily oral levodopa dosing Yes
8. Activities of daily living limitation,
severity level
Moderate or severe
9. Falling, frequency Most of the time or all
the time
10. Dementia, severity level Moderate or severe
11. Psychosis, severity level Moderate or Severe
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(K = 0.430; 95% CI, 0.397–0.464; Additional file 1: Table
S2). Correlations with physician’s judgment were signifi-
cant for the Delphi criteria of ≥5 times daily oral levo-
dopa dosing (p < 0.0001) and level of limitation of
activities of daily living (p = 0.0022). Physician’s judg-
ment of APD also correlated with UPDRS II score
(p < 0.05), Hoehn and Yahr score (p < 0.0001), NMSS
score (p < 0.05), time since diagnosis (p < 0.0001),
current invasive PD treatment (p < 0.0001), motor fluc-
tuations (p < 0.0001), existence of caregiver support
(p < 0.001), and type of residence (p < 0.05)
(Additional file 1: Table S3).
DAT eligibility according to physician’s judgment
Of 1342 APD patients, 882 (66%) patients were eligible
for DAT and 34% (n = 460) were ineligible. Of 1272
non-APD patients, 127 (10%) patients were eligible for
DAT. Of 882 APD DAT-eligible patients, 384 (43.6%)
had ongoing DAT, 164 (18.6%) had decided to initiate
DAT during the study visit, and 332 (37.7%) had no
DAT planned (data were unavailable for two subjects).
Patients deemed eligible but who had no DAT planned
listed the need for more time to decide (39%) and/or pa-
tient refusal (25%) as primary reasons for not using DAT
(Table 5).
A comparison of baseline characteristics by DAT eligi-
bility is shown in Table 6. Of 384 patients currently on
DAT, 57% were using DBS, 39% were using LCIG, and
Table 2 APD and non-APD by country based on investigator’s
judgment
Country, n (%) APD Non-APD
Australia 61 (61) 39 (39)
Austria 73 (61) 47 (39)
Belgium 77 (46) 90 (54)
Canada 78 (32) 164 (68)
Croatia 32 (58) 23 (42)
Czech Republic 60 (82) 13 (18)
Germany 122 (69) 55 (31)
Greece 65 (38) 105 (62)
Hungary 50 (50) 50 (50)
Ireland 29 (24) 90 (76)
Israel 70 (58) 50 (42)
Italy 60 (43) 80 (57)
Romania 95 (59) 66 (41)
Russia 106 (42) 144 (58)
Slovakia 102 (80) 26 (20)
Slovenia 45 (46) 54 (54)
Switzerland 93 (69) 41 (31)
Turkey 124 (48) 136 (52)
ADP advanced Parkinson’s disease, non-APD non-advanced Parkinson’s disease
Table 3 Characteristics of ADP and non-ADP based on physician’s judgment
APD, N = 1342 Non-APD, N = 1273
Characteristics n/N (%) Mean (SD) n/N (%) Mean (SD)
Age, years 67.6 (9.4)
n = 1338
66.4 (10.3)
n = 1272
Sex, male 817/1342 (61) 734/1273 (58)
Living at home 1304/1342 (97) 1264/1273 (99)
Required caregiver support, yes 917/1327 (69) 328/1270 (26)
Time since diagnosis, years 11.0 (5.8)
n = 1304
4.3 (3.7)
n = 1249
Motor fluctuations present, yes 1167/1342 (87) 295/1273 (23)
Duration of motor fluctuations, years 4.9 (3.9)
n = 1151
2.3 (2.1)
n = 272
UPDRS V: Modified Hoehn & Yahr score 2.9 (0.8)a
N = 1342
2.0 (0.6)a
n = 1272
Eligible for invasive treatment options, yes 882/1342 (66) 127/1272 (10)
Status of invasive treatment for eligible patients
Ongoing 384/882 (44) 15/127 (12)
Decided at visit to start 164/882 (19) 17/127 (13)
No 332/882 (38) 91/127 (72)
Missing 2/882 (0.2) 4/127 (3.1)
aThe UPDRS was measured in the “On” state. Statistical significance based on a t test comparison between APD and non-APD patients are indicated at the p <
0.0001. All proportions except for the invasive treatment status included patients with no missing data. APD advanced Parkinson’s disease, non-APD non-advanced
Parkinson’s disease, PD Parkinson’s disease, SD standard deviation, UPDRS Unified Parkinson’s Disease Rating Scale
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8% were receiving CSAI (patients were not limited to
only one DAT). Mean (SD) duration of DBS treatment,
LCIG therapy, and CSAI was 39.9 (41.5) months, 20.3
(20.1) months, and 22.6 (27.6) months, respectively. The
number of current PD treatments per APD patient
ranged from one to six (one, 19.7%; two, 33.6%; three,
28.5%; four, 12.0%; five, 3.8%; and six, 0.3%).
Patients with APD currently receiving DAT had sig-
nificantly lower impairment in ADL compared with
APD patients who had planned DAT (p = 0.0389) and
compared with APD patients who had no DAT planned
(p = 0.0048) (Fig. 2a). Patients who were currently re-
ceiving DAT had significantly lower impairment in
motor symptoms compared with patients who had
planned DAT (p = 0.0002) and those who had no DAT
planned (p < 0.0001); motor symptom severity was also
significantly lower in the combined DAT-eligible group
compared with DAT-ineligible patients (p = 0.0047).
Patients currently receiving DAT had significantly lower
scores for dyskinesia duration than those with planned
DAT (p = 0.0140). Dyskinesia disability was significantly
lower for patients with ongoing DAT compared with
patients who had DAT planned (p < 0.0001) and with pa-
tients who had no DAT planned (p = 0.0067) (Fig. 2b).
Average duration of “Off” time was significantly lower for
patients receiving ongoing DAT compared with patients
who had planned DAT (p < 0.0001), and with patients
who had no DAT planned (p < 0.0001) (Fig. 2c). Patients
currently receiving DAT had significantly lower NMSS
total scores than patients with no DAT planned
(p = 0.0171) (Fig. 2d).
Dyskinesia duration and disability scores and “Off”
time were significantly lower in DAT-ineligible patients
than in DAT-eligible patients who are not yet treated
(p < 0.0001 for all). QoL was significantly better in
DAT-ineligible patients than in the combined DAT-
eligible patient group (p = 0.0064).
Discussion
The progressive nature of PD means that categorical
sorting of patients into distinct disease stages might
help to ensure implementation of best practices and
effective treatment strategies. As PD progresses, oral
pharmacotherapeutic strategies may not be as efficient
in some patients, and more invasive DAT (e.g.
continuous-infusion therapies [CSAI and LCIG] and
DBS) need to be initiated to manage symptoms and
maintain QoL [5]. Clinical indicators for categorizing
APD are ambiguous and subjective, presenting unmet
needs for enhanced descriptions and guidelines
Fig. 1 Clinical PD assessments in APD versus non-APD patients. a Activities of daily living (UPDRS II) and motor symptom severity (UPDRS III), b
dyskinesia duration and disability (UPDRS Part IV Q32 and Q33), c average duration of “Off” time (UPDRS Part IV Q39), and (d) NMS burden and
quality of life (PDQ-8). Error bars indicate the standard deviation. p values from a paired t test indicate statistical significance. APD = Advanced
Parkinson’s disease; non-APD = Non-advanced Parkinson’s disease; NMSS = Non-motor Symptom Scale; PDQ-8 = Parkinson’s disease 8-item
questionnaire; SD = Standard deviation; UPDRS = Unified Parkinson’s Disease Rating Scale
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relating to the staging of APD and precise timeframes
for DAT implementation. Current classification
methods based on motor symptom trajectory do not
provide a comprehensive patient profile to accurately
characterize the multidimensional features of motor
and non-motor manifestations accompanying APD.
The current study aimed to determine the proportion
of PD patients identified as having APD according to
physician’s assessment, to compare the clinical fea-
tures of APD and non-APD patients, and to compare
newly developed Delphi criteria for APD with physi-
cian’s judgment. The current study is the first report
to include international data on the proportion of
APD, clinical features, evaluation of physician’s judg-
ment, use of the Delphi criteria in routine clinical
practice, gaps in patient identification, and standard
patient scores.
The key limitations of the regularly used Hoehn &
Yahr staging is the neglect of non-motor symptoms and
levodopa-induced complications (e.g. motor fluctuations,
dyskinesia) which strongly contribute to impaired QoL
in APD [11]. We found a moderate correlation between
physician’s judgment and Delphi criteria for APD, indi-
cating some consensus already. Approximately half of
the PD patients at movement disorder clinics were clas-
sified by the physician as APD, although the range varied
considerably in certain countries. These variations high-
light the inconsistencies among health systems, move-
ment disorders clinics, and physicians in differing
regions to categorize APD and may be based on differ-
ent intercultural disease perceptions and treatment avail-
abilities. The high proportion of APD classification
(i.e. 51%) by clinician judgment is not meant to
Table 5 Reasons patients with APD were not using DAT
Reasona Patients, n (%), n = 332
Patient characteristic reasons
Cognitive-related issues 27 (8)
Psychiatric-related issues 23 (7)
Comorbidities 20 (6)
Age 12 (4)
Lack of caregiver/family support 11 (3)
Motor function–related issues 6 (2)
Reasons related to patient decision
Patient needs more time to decide 129 (39)
Patient refusal 82 (25)
Other reasons
Cost/reimbursement 0
Other reasons 45 (14)
aMultiple entries for each patient were possible. A total of 23 patients who
gave reasons related to patient decisions and had physician-based patient
characteristic reasons were excluded
APD advanced Parkinson’s disease, DAT device-aided treatment
Table 4 Correlations between physician’s judgment of APD and individual Delphi criteria for APD
Odds ratio
Prognostic parameter Regression coefficient Adjusted estimate 95% Wald CI p value
Troublesome motor fluctuations
(severity level, moderate/severe versus mild)
0.1122 1.119 0.743 1.684 0.5909
“Off” time
(hours/waking day, ≥ 2 h versus < 2 h
0.0190 1.019 0.691 1.503 0.9235
Nighttime sleep disturbances
(severity level, moderate/severe versus mild)
0.0167 1.017 0.744 1.389 0.9166
Troublesome dyskinesia
(hours/waking day, ≥ 2 h versus < 2 h)
0.3610 1.435 0.827 2.490 0.1993
Non-motor fluctuations present
(yes versus no)
0.1763 1.193 0.893 1.593 0.2322
“Off” time at least every 3 h
(yes versus no)
0.3944 1.483 0.978 2.251 0.0638
≥ 5 times daily oral levodopa dosing
(yes versus no)
0.7417 2.100 1.544 2.854 < 0.0001a
Activities of daily living limitation
(severity level, moderate/severe versus mild)
0.5389 1.714 1.213 2.422 0.0022a
Falling
(frequency, most/all the time versus some of the time)
0.0432 1.044 0.397 2.744 0.9302
Dementia
(severity level, moderate/severe versus mild)
−0.4134 0.661 0.399 1.097 0.1093
Psychosis
(severity level, moderate/severe versus mild)
0.5745 1.776 0.846 3.731 0.1291
aCorrelations with physician’s judgment were significant for the Delphi criteria ≥5 times daily oral levodopa dosing (p < 0.0001) and activities of daily living
limitation (p = 0.0022). APD advanced Parkinson’s disease, CI confidence interval
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Table 6 Baseline characteristics of DAT-eligible and DAT-ineligible patients with APD
Characteristics DAT-eligible, n = 882a
Ongoing DAT
n = 384
Planned DAT
n = 164
Not planned
n = 332
DAT-ineligible
n = 460
Demographics
Age, years, mean (SD) 65.1 (8.7)
n = 383
64.3 (9.0)
n = 163
67.8 (9.6)
n = 330
70.6 (9.1)
Sex, male, n (%) 239 (62) 103 (63) 200 (60) 274 (60)
Caregiver support, n (%) 278 (73)
n = 380
109 (67)
n = 162
242 (74)
n = 328
286 (63)
Medical history
PD duration, years, mean (SD) 14.2 (5.6)
n = 372
10.1 (4.7)
n = 160
11.1 (5.0
n = 322
8.6 (5.5)
n = 449
Motor fluctuations, n (%) 353 (92) 154 (94) 320 (96) 338 (74)
Motor fluctuation duration years, mean (SD) 7.2 (4.3)
n = 351
4.2 (2.8)
n = 152
4.4 (3.5)
n = 312
3.3 (2.9)
n = 334
Comorbidity, n (%) 327 (85) 135 (82) 301 (91) 431 (94)
Time since referral to center, years, mean (SD) 5.2 (5.5)
n = 305
2.7 (3.7)
n = 119
4.7 (4.8)
n = 231
4.0 (4.6)
n = 340
atwo patients had missing data
APD advanced Parkinson’s disease, DAT device-aided treatment, PD Parkinson’s disease, SD standard deviation
Fig. 2 Clinical PD assessments based on DAT eligibility and status. Comparisons between DAT groups (ongoing, planned, not planned, and
ineligible) are shown for (a) activities of daily living (UPDRS II) and motor symptom severity (UPDRS III), b dyskinesia duration and disability
(UPDRS Part IV Q32 and Q33), c average duration of “Off” time (UPDRS Part IV Q39), and (d) NMS burden and QoL (PDQ-8). Error bars indicate the
standard deviation. p values from a paired t test indicate statistical significance. An asterisk indicates significant differences between DAT-ineligible
patients and all DAT-eligible patients combined. DAT = Device-aided treatment; NMSS = Non-motor Symptom Scale; NS = Not significant; PDQ-8
= Parkinson’s disease 8-item questionnaire; SD = Standard deviation; UPDRS = Unified Parkinson’s Disease Rating Scale
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represent an epidemiological prevalence in the PD pa-
tient population as judgment is likely biased by patient
selection from only movement disorder centers that tend
to treat more advanced-stage PD patients. Patients who
were characterized as having APD had worse motor and
NMS severity and reduced QoL compared with
non-APD patients. This is consistent with findings from
other studies showing disease characteristics [12] and
motor and non-motor features in APD [13]. Both groups
were similar regarding age, sex, and living situation, but
differed in terms of caregiver support status, which is
likely an effect of having APD.
Delphi criteria have been previously used by other in-
vestigators to define APD. The CEPA study [14] catego-
rized APD symptoms by definitive symptoms, probable
symptoms, and possible symptoms. The authors’ list of
symptom coverage is extensive and generally covered by
our targeted Delphi criteria, which allows a more struc-
tured and simplistic method of assessment. Longer time
since diagnosis, dyskinesia duration, and limitations of
ADL are reported to be predictors for the diagnosis of
APD [6]. That 87.0% of APD (versus 23.2% in non-APD)
patients were reported as having motor fluctuations may
hint that physician’s judgment was strongly based on
motor fluctuations. Compared with Delphi criteria for
APD, which subsumes a broader range of symptoms
under the diagnosis of APD, physician’s judgment, based
primarily on motor fluctuations, is too narrow.
Of APD patients, 66% were considered eligible for
DAT. Within this group, many patients had ongoing
DAT or had made the decision to initiate DAT. How-
ever, almost one-third of DAT-eligible patients did not
plan on initiating DAT at the time of their study visit,
demonstrating that patients did not elect to follow their
clinician’s suggested optimal treatment plan. Most
DAT-eligible patients were not currently using DAT
based on personal decision (outright refusal or the need
for more time to decide). Transitioning from oral drug
administration to more invasive measures is an import-
ant step for patients; therefore, it is not surprising that
many patients initially decline to move forward with
DAT or request more time to discuss and educate them-
selves prior to initiating the change in treatment. The
large percentage of patients delaying their DAT initiation
suggests a need for enhanced patient-physician guidance
on navigating the transition to DAT for optimal pa-
tient outcomes, while still incorporating patient pref-
erences [15, 16].
Further evaluations compared patient clinical out-
comes as they related to DAT eligibility status. Gener-
ally, DAT-eligible patients had worse motor symptoms
and QoL than did DAT-ineligible patients. Patients who
were currently receiving DAT at the time of the study
had significantly lower impairment in ADL, motor
function, dyskinesia duration and disability, “Off” time,
and lower NMSS total scores than did patients who were
not currently on DAT (whether or not they were planning
to initiate DAT). These findings are similar to other stud-
ies that demonstrated DAT improvement of motor and
non-motor complications associated with APD [17, 18].
The fact that the Delphi criteria include two items on
NMS (nighttime sleep and non-motor fluctuations) may
make it more suitable to obtain a comprehensive patient
profile to determine advanced PD or DAT eligibility. Evi-
dence from the GLORIA registry, which sampled the lar-
gest cohort of advanced PD patients treated with LCIG in
routine clinical care, showed NMS improvements in pa-
tients treated with DAT (i.e. LCIG) in multiple NMSS do-
mains [19, 20]. These findings further demonstrate that
non-motor features of APD can be improved with opti-
mized dopaminergic delivery. Of note, not all APD pa-
tients are candidates for DAT (eg, patients with dementia)
and some non-APD patients may still be candidates for
DAT because they have demanding functional needs (eg,
young working individuals), they may be using DAT for
the (non-approved) treatment of non-motor symptoms or
for treatment of PD-related tremor, or they may have poor
tolerability of oral levodopa. However, the reasons for
non-APD use of DAT were not captured in the study and
therefore remain speculative.
Patient baseline characteristics are in keeping with
clinical reports in which DATs are implemented. Weaver
and colleagues [18] report patient characteristics for 121
dB candidates with APD, showing similar age and living
situation but fewer patients with caregiver support com-
pared with patients in the current study. Patients in the
current study who were receiving DBS have similar
scores as noted in the DAT-eligible group in UPDRS II
assessments but scored lower in motor function as de-
termined by UPDRS III compared with that reported by
Weaver et al. [18]. A report from Garcia Ruiz and col-
leagues [17] summarizes patient characteristics from 20
open-label studies using CSAI in patients with APD.
DAT-eligible patients from the current study showed
similar duration of disease but lower mean age com-
pared with all CSAI studies. Patients treated with LCIG
also demonstrated similar age of DAT onset, duration of
disease, and gender ratio [21].
This study utilized practicing clinicians and a large
sample size of patients from multiple countries who
were currently seeking medical support. It is important
to note that the study was not designed to be an epi-
demiological study and the goal was not specifically to
determine the percentage of APD patients (prevalence)
using that methodology. The collected data demonstrate
real-world evidence of treatment patterns and highlight
gaps in current clinical care and possible areas for im-
provement. A study limitation and bias were noted
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regarding recruitment of inpatients at movement dis-
order clinics, possibly resulting in increased prevalence
of (hospitalized) patients with more advanced PD. Clin-
ical sites were chosen based on, among other aspects,
availability of DAT. This likely contributed to the dispro-
portionate representation of DAT modalities (i.e. more
patients using LCIG). A bias may have occurred when
the investigators were trained for the study where the in-
vestigators were informed about the Delphi criteria, set
up by their peer movement disorder specialists, which
may potentially have influenced their understanding and
judgment. Another limitation to the study is the post
hoc nature of the analysis regarding DAT eligibility. In
addition, study results were only obtained from a single,
independent patient visit. Without follow-up, it is un-
known if DAT-eligible patients who were not currently
using DAT have changed their minds and chose DAT or
if DAT-ineligible patients have had a change in their
DAT eligibility after this study concluded.
The present study reports findings from a cross-sectional,
international, observational study of patients with PD. This
study highlights the inconsistency in physician judgment
for DAT eligibility and the actual number of patients con-
sidering it. The observed heterogeneity in patient identifica-
tion results in increased numbers of patients with a delayed
diagnosis of APD and, therefore, higher numbers of pa-
tients who do not receive optimized medical treatment.
Conclusions
There is a need for consistent criteria by which APD can
be detected earlier, thereby allowing patients to ad-
equately prepare for changing medical needs that arise
in advancing stages of the disease. The Delphi criteria
highlight some key criteria that are both quantifiable
and tangible for the patient and the physician. These cri-
teria will help to increase the awareness for these symp-
toms and further emphasize the need to screen these
symptoms. Improving treatment for this patient popula-
tion begins with the optimization of oral dopamine re-
placement therapies, which is dependent on the correct
diagnosis of the disease stage and medication require-
ment. Altogether, these findings aid in further
categorization of patients into APD and suggest the Del-
phi criteria for APD may be a useful assessment tool
to aid patient classification and demonstrate the bene-
fit of DAT in APD patients. Further studies are
needed to validate and evaluate the use of these cri-
teria in routine clinical practice.
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